Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PD-1/PD-L1-IN-9 是一种有效和具有口服活性的 PD-1/PD-L1 相互作用抑制剂,IC50 值为 3.8 nM。PD-1/PD-L1-IN-9 可以增强免疫细胞对肿瘤细胞的杀伤活性。PD-1/PD-L1-IN-9 在 CT26 小鼠模型中表现出显着的体内抗肿瘤活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 928 | 现货 | ||
2 mg | ¥ 1,370 | 现货 | ||
5 mg | ¥ 2,320 | 现货 | ||
10 mg | ¥ 3,480 | 现货 | ||
25 mg | ¥ 5,550 | 现货 | ||
50 mg | ¥ 7,550 | 现货 | ||
100 mg | ¥ 9,870 | 现货 | ||
500 mg | ¥ 19,800 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,550 | 现货 |
产品描述 | PD-1/PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1/PD-L1 interaction. It enhances the immune cells' ability to kill tumor cells and demonstrates significant antitumor activity in vivo in a CT26 mouse model. |
体外活性 | PD-1/PD-L1-IN-9 (46.9-1500 nM; pretreated for 2 h) dose-dependently significantly activates the antitumor immunity of PBMCs to MDB-MB 231 cells, EC50 = ∼100 nM[1]. |
体内活性 | PD-1/PD-L1-IN-9 (40-80 mg/kg; p.o. once a day for 2 weeks) inhibits tumor growth in a dose-dependent manner and does not cause any body weight loss or mortality of mice. PD-1/PD-L1-IN-9 (3 mg/kg; a single i.v.) exhibits half-life (t1/2=4.2 h), plasma clearance (Cl=11.5 L/h/kg) and Cmax (1233 ng/mL) in rats. PD-1/PD-L1-IN-9 (25 mg/kg; a single p.o.) exhibits moderate oral bioavailability (F=22 %), half-life (t1/2=6.4 h) and Cmax (192 ng/mL) in rats[1]. |
分子量 | 348.44 |
分子式 | C22H24N2O2 |
CAS No. | 2628506-54-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 90 mg/mL (258.3 mM), Sonification is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.8699 mL | 14.3497 mL | 28.6993 mL | 71.7484 mL |
5 mM | 0.574 mL | 2.8699 mL | 5.7399 mL | 14.3497 mL | |
10 mM | 0.287 mL | 1.435 mL | 2.8699 mL | 7.1748 mL | |
20 mM | 0.1435 mL | 0.7175 mL | 1.435 mL | 3.5874 mL | |
50 mM | 0.0574 mL | 0.287 mL | 0.574 mL | 1.435 mL | |
100 mM | 0.0287 mL | 0.1435 mL | 0.287 mL | 0.7175 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
PD-1/PD-L1-IN-9 2628506-54-5 Apoptosis Cell Cycle/Checkpoint Immunology/Inflammation PD-1/PD-L1 PD1/PDL1IN9 PD 1/PD L1 IN 9 Inhibitor inhibitor inhibit